% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hfner:126647,
      author       = {M. F. Häfner and F. Roeder$^*$ and F. Sterzing$^*$ and D.
                      Krug and S. A. Koerber and J. Kappes and H. Hoffmann and A.
                      Slynko$^*$ and J. Debus$^*$ and M. Bischof},
      title        = {{P}ostoperative radiotherapy of patients with thymic
                      epithelial tumors ({TET}): a retrospective analysis of
                      outcome and toxicity.},
      journal      = {Strahlentherapie und Onkologie},
      volume       = {191},
      number       = {2},
      issn         = {0179-7158},
      address      = {Heidelberg},
      publisher    = {Springer51814},
      reportid     = {DKFZ-2017-02675},
      pages        = {133-140},
      year         = {2015},
      abstract     = {The purpose of this study was to evaluate postoperative
                      radiotherapy regarding outcome and toxicity in patients with
                      thymic epithelial tumors (TET) after surgery.We
                      retrospectively analyzed medical records of 41 patients with
                      TET treated with postoperative radiotherapy at our
                      institution between 1995 and 2012. The impact of prognostic
                      factors (e.g., Masaoka stage, histological subtype) was
                      investigated and radiation-related toxicity was
                      assessed.Median age was 59.8 years and median follow-up was
                      61 months. In $24.4 \%,$ TETs were associated with
                      paraneoplastic syndromes. The 5-year overall survival (OS)
                      was $89.5 \%$ and the 5-year disease-free survival (DFS)
                      was $88.9 \%.$ Masaoka stage had a significant impact on
                      OS (p = 0.007). Locally limited stages I + II had a
                      5-year OS of $100 \%$ compared to $80 \%$ for stage III
                      and $66.7 \%$ for stage IV. The 5-year DFS was excellent
                      with $100 \%$ for both WHO groups A/AB/B1 and B2,
                      respectively, and significantly (p = 0.005) differed
                      from B3/C-staged patients with a 5-year DFS of $63.6 \%.$
                      Resection status, paraneoplastic association, radiation
                      dose, or tumor size did not influence survival. There were
                      no high-grade acute or late side effects caused by
                      radiotherapy.Masaoka stage has a significant impact on OS as
                      WHO type has on DFS in patients with TETs after surgery and
                      adjuvant irradiation. Postoperative radiotherapy with doses
                      around 50 Gy is safe and not likely to cause high-grade
                      toxicity. Further prospective trials are necessary to
                      separate patient subgroups that benefit from radiotherapy
                      from those that do not.},
      cin          = {E055 / E050 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E055-20160331 / I:(DE-He78)E050-20160331 /
                      I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25156510},
      doi          = {10.1007/s00066-014-0740-z},
      url          = {https://inrepo02.dkfz.de/record/126647},
}